DrugPatentWatch Database Preview
Email this page to a colleague
« Back to Dashboard
Evogliptin is an investigational drug.
There have been 21 clinical trials for Evogliptin. The most recent clinical trial was a Phase 3 trial, which was initiated on February 1st 2021.
The most common disease conditions in clinical trials are Diabetes Mellitus, Type 2, Diabetes Mellitus, and Liver Diseases. The leading clinical trial sponsors are Dong-A ST Co., Ltd., REDNVIA, and Samsung Medical Center.
There are forty-six US patents protecting this investigational drug and five hundred and ninety-seven international patents.
Recent Clinical Trials for Evogliptin
|A Clinical Trial to Evaluate the Bone Metabolism and the Blood Sugar of Evogliptin and Dapagliflozin||Dong-A ST Co., Ltd.||Phase 4|
|A Clinical Trial to Evaluate the Bone Metabolism and the Blood Sugar of Evogliptin and Dapagliflozin||Kyung Hee University Hospital at Gangdong||Phase 4|
|A Clinical Trial to Evaluate the Preference Regarding Convenience of Medication and Efficacy/Safety of SUGAMET®XR Tablet 5/1000mg||Dong-A ST Co., Ltd.||Phase 4|
Top disease conditions for Evogliptin
Top clinical trial sponsors for Evogliptin
|Drugname||Patent Number||Patent Title||Patent Assignee||Estimated Expiration|
|Evogliptin||⤷ Try it Free||Antidiabetic tricyclic compounds||Merck Sharp & Dohme (Rahway, NJ)||⤷ Try it Free|
|Evogliptin||⤷ Try it Free||[5,6]--fused bicyclic antidiabetic compounds||Merck Sharp & Dohme Corp. (Rahway, NJ)||⤷ Try it Free|
|Evogliptin||⤷ Try it Free||[7,6]-fused bicyclic antidiabetic compounds||Merck Sharp & Dohme Corp. (Rahway, NJ)||⤷ Try it Free|
|Evogliptin||⤷ Try it Free||Controlled release dosage form||TRIASTEK, INC. (Nanjing, CN)||⤷ Try it Free|
|Evogliptin||⤷ Try it Free||Composition containing a DPP-IV inhibitor for preventing or treating renal diseases||DONG-A ST Co., Ltd (Seoul, KR)||⤷ Try it Free|
|Evogliptin||⤷ Try it Free||Functionalized Exendin-4 derivatives||SANOFI (Paris, FR)||⤷ Try it Free|
|>Drugname||>Patent Number||>Patent Title||>Patent Assignee||>Estimated Expiration|
|Drugname||Country||Document Number||Estimated Expiration||Related US Patent|
|Evogliptin||Australia||AU2015263620||2034-05-22||⤷ Try it Free|
|Evogliptin||Canada||CA2947781||2034-05-22||⤷ Try it Free|
|Evogliptin||China||CN106458913||2034-05-22||⤷ Try it Free|
|Evogliptin||European Patent Office||EP3145915||2034-05-22||⤷ Try it Free|
|Evogliptin||Japan||JP2017516771||2034-05-22||⤷ Try it Free|
|Evogliptin||South Korea||KR20170005861||2034-05-22||⤷ Try it Free|
|>Drugname||>Country||>Document Number||>Estimated Expiration||>Related US Patent|